BNP Paribas Financial Markets
TRAX

BNP Paribas Financial Markets’s First Tracks Biotherapeutics TRAX Stock Holding History

BNP Paribas Financial Markets’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
+5,162
New +$96.5K ﹤0.01% 4523

Other funds holding TRAX

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BNP Paribas Financial Markets's TRAX Position: Q2 2026 in Review

BNP Paribas Financial Markets opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 5,162 shares worth $104K. The stake represents ﹤0.01% of the portfolio and ranks #4523 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • BNP Paribas Financial Markets held 5,162 shares of First Tracks Biotherapeutics worth $104K as of Q2 2026.
  • First Tracks Biotherapeutics was a new BNP Paribas Financial Markets position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4523 holding.
  • 89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.